Harrow Health Inc（纳斯达克代码：HROW）宣布，将启动一项关键的三期临床试验。该试验旨在寻求扩大其核心产品Triesence®的标签适应症范围，计划纳入白内障手术后并发的眼部炎症及疼痛管理。
若临床试验结果达到预期终点，Triesence®将成为首个获准用于该术后症状的皮质类固醇药物。此举有望为白内障术后患者提供一种新的、有效的治疗选择，并进一步拓宽Triesence®的市场应用空间。
Harrow Health Inc（纳斯达克代码：HROW）宣布，将启动一项关键的三期临床试验。该试验旨在寻求扩大其核心产品Triesence®的标签适应症范围，计划纳入白内障手术后并发的眼部炎症及疼痛管理。
若临床试验结果达到预期终点，Triesence®将成为首个获准用于该术后症状的皮质类固醇药物。此举有望为白内障术后患者提供一种新的、有效的治疗选择，并进一步拓宽Triesence®的市场应用空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.